205 related articles for article (PubMed ID: 19732776)
1. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Wu X; Sun L; Zha W; Studer E; Gurley E; Chen L; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Wang G; Chen J; Wang JY; Zhou H
Gastroenterology; 2010 Jan; 138(1):197-209. PubMed ID: 19732776
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells.
Zhou H
Methods Enzymol; 2011; 490():107-19. PubMed ID: 21266246
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.
Lei B; Zha W; Wang Y; Wen C; Studer EJ; Wang X; Jin F; Wang G; Zhang L; Zhou H
Mol Pharm; 2010 Jun; 7(3):844-53. PubMed ID: 20349948
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytes.
Zha BS; Wan X; Zhang X; Zha W; Zhou J; Wabitsch M; Wang G; Lyall V; Hylemon PB; Zhou H
PLoS One; 2013; 8(3):e59514. PubMed ID: 23533630
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.
Taura M; Kariya R; Kudo E; Goto H; Iwawaki T; Amano M; Suico MA; Kai H; Mitsuya H; Okada S
Free Radic Biol Med; 2013 Dec; 65():778-788. PubMed ID: 23973637
[TBL] [Abstract][Full Text] [Related]
6. HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS.
Deng W; Baki L; Yin J; Zhou H; Baumgarten CM
J Mol Cell Cardiol; 2010 Nov; 49(5):746-52. PubMed ID: 20736017
[TBL] [Abstract][Full Text] [Related]
7. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
8. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers.
Lee GA; Rao M; Mulligan K; Lo JC; Aweeka F; Schwarz JM; Schambelan M; Grunfeld C
AIDS; 2007 Oct; 21(16):2183-90. PubMed ID: 18090045
[TBL] [Abstract][Full Text] [Related]
9. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
Barrail-Tran A; Morand-Joubert L; Poizat G; Raguin G; Le Tiec C; Clavel F; Dam E; Chêne G; Girard PM; Taburet AM;
Antimicrob Agents Chemother; 2008 May; 52(5):1642-6. PubMed ID: 18285478
[TBL] [Abstract][Full Text] [Related]
10. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
11. The role of CCAAT enhancer-binding protein homologous protein in human immunodeficiency virus protease-inhibitor-induced hepatic lipotoxicity in mice.
Wang Y; Zhang L; Wu X; Gurley EC; Kennedy E; Hylemon PB; Pandak WM; Sanyal AJ; Zhou H
Hepatology; 2013 Mar; 57(3):1005-16. PubMed ID: 23080229
[TBL] [Abstract][Full Text] [Related]
12. Select HIV protease inhibitors alter bone and fat metabolism ex vivo.
Jain RG; Lenhard JM
J Biol Chem; 2002 May; 277(22):19247-50. PubMed ID: 11937496
[TBL] [Abstract][Full Text] [Related]
13. HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages.
Chen L; Jarujaron S; Wu X; Sun L; Zha W; Liang G; Wang X; Gurley EC; Studer EJ; Hylemon PB; Pandak WM; Zhang L; Wang G; Li X; Dent P; Zhou H
Biochem Pharmacol; 2009 Jul; 78(1):70-7. PubMed ID: 19447225
[TBL] [Abstract][Full Text] [Related]
14. Prevention of HIV protease inhibitor-induced dysregulation of hepatic lipid metabolism by raltegravir via endoplasmic reticulum stress signaling pathways.
Cao R; Hu Y; Wang Y; Gurley EC; Studer EJ; Wang X; Hylemon PB; Pandak WM; Sanyal AJ; Zhang L; Zhou H
J Pharmacol Exp Ther; 2010 Aug; 334(2):530-9. PubMed ID: 20472667
[TBL] [Abstract][Full Text] [Related]
15. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Oldfield V; Plosker GL
Drugs; 2006; 66(9):1275-99. PubMed ID: 16827606
[TBL] [Abstract][Full Text] [Related]
16. Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamics.
De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Hoetelmans RM; Cauda R
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):359-66. PubMed ID: 15097152
[TBL] [Abstract][Full Text] [Related]
17. Human immunodeficiency virus protease inhibitors modulate Ca2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes.
Kao E; Shinohara M; Feng M; Lau MY; Ji C
Hepatology; 2012 Aug; 56(2):594-604. PubMed ID: 22407670
[TBL] [Abstract][Full Text] [Related]
18. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells.
Bode H; Lenzner L; Kraemer OH; Kroesen AJ; Bendfeldt K; Schulzke JD; Fromm M; Stoltenburg-Didinger G; Zeitz M; Ullrich R
Antivir Ther; 2005; 10(5):645-55. PubMed ID: 16152758
[TBL] [Abstract][Full Text] [Related]
19. HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Liu R; Zhang L; Yang J; Zhang X; Mikkelsen R; Song S; Zhou H
PLoS One; 2015; 10(5):e0125928. PubMed ID: 25933118
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
Raguin G; Chêne G; Morand-Joubert L; Taburet AM; Droz C; Le Tiec C; Clavel F; Girard PM;
Antivir Ther; 2004 Aug; 9(4):615-25. PubMed ID: 15456093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
